CABA News and Press, Cabaletta Bio Inc. From 02/18/24

2024-02-18 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-08 09:45:10 ET iShares 0-3 Month Treasury Bond ETF (SGOV) SGOV is trading UP for the last 5 days, and it at trading at $100.41 with volume of 1,285,969 and a one day change of $0.04 (0.04%). iShares 0-3 Month Treasury Bond ETF has a 52-week low of 100.04 and a 52-week high o...

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administrati...

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Exe...

2024-01-31 02:53:09 ET Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treat...

2024-01-17 11:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-08 15:05:33 ET More on Cabaletta Bio Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology Buy Cabaletta Bio's Promising SLE Treatment Cabaletta Bio GAAP EPS of -$0.37 beats by $0.04 Cantor starts Cabaletta at overweight, cites "strong" positi...

– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development and review of CABA-201 for the treatment of these autoimmune diseases – PHI...

PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Exe...

2023-12-11 05:58:05 ET Summary Cabaletta Bio is developing targeted cellular therapies for autoimmune diseases, including systemic lupus erythematous and myositis. Their lead program, CABA-201, is a CD19 chimeric antigen receptor (CAR) T cell therapy currently in phase 1/2 clinica...